PerkinElmer Launches New Panels of AlphaLISA® "No Wash" Immunoassay Kits for Research in Angiogenesis, Inflammation and Cancer
New Orleans, Louisiana – At Experimental Biology 2009, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today unveiled a major new series of AlphaLISA® “No Wash” immunoassay kits to help enable advanced biomarker research in multiple key disease states, including angiogenesis, inflammation and cancer.
This latest release brings the number of available AlphaLISA® assays to 54 kits and is a broad expansion of PerkinElmer’s breakthrough ELISA-alternative ALPHA (Amplified Luminescent Proximity Homogeneous Assay) technology portfolio.
AlphaLISA® is a powerful proprietary bead-based platform that allows the highly sensitive detection of biomolecules and biomolecular interactions without cumbersome wash steps, enabling researchers to measure very low affinity interactions. AlphaLISA® saves time and eliminates labor intensive processes that are difficult to automate and it overcomes other traditional limitations of ELISAs, such as assay variation and narrow dynamic range. The technology’s sensitivity and homogeneity also enables savings in precious sample and antibodies usage.
“The ability to simplify assays is absolutely critical to laboratory workflow," said Richard M. Eglen, Ph.D., president, Biodiscovery, PerkinElmer. "With compelling advantages over conventional ELISA and other plate-based assays as well as high sensitivity, AlphaLISA® provides key advantages in efficiency and discovery in human health research.”
In addition to angiogenesis, inflammation, and cancer biomarker research assays, the newest AlphaLISA® kits feature panels of assays for research in Alzheimer’s, cardiovascular, and metabolic disorders.
The list of 23 new AlphaLISA® immunoassay kits* includes:
| Analyte | Analyte For Research On |
|---|
| VEGFB | Angiogenesis |
| VEGFC | Angiogenesis |
| VEGFD | Angiogenesis |
| sAPPa | Alzheimer’s |
| sAPPb | Alzheimer’s |
| AFP | Cancer |
| EPO-R | Cancer |
| ERBB 2/HER 2 | Cancer |
| MMP1 | Cancer |
| MMP9 | Cancer |
| b-NGF | Cancer |
| Myeloperoxidase | Cardiovascular |
| NT-proBNP | Cardiovascular |
| Renin | Cardiovascular |
| tPA | Cardiovascular |
| CRP | Inflammation |
| IL1a | Inflammation |
| IL12(p70) | Inflammation |
| IL13 | Inflammation |
| IL18 | Inflammation |
| CCL2/MCP1 | Inflammation |
| IGF1 | Metabolism |
| IGF2 | Metabolism |
AlphaLISA® is a proprietary homogeneous bead-based assay, and has been validated with PerkinElmer's EnVision® Multiplate Label Readers, a highly flexible modular system that detects several assay formats, including TR-FRET, luminescence and fluorescence.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
* For research use only. Not for use in diagnostic procedures.
Media Contact:
Mario Fante
PerkinElmer, Inc.
Email: mario.fante@perkinelmer.com
Phone: 781-663-5602